Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Based in Paris, France, Neovacs S.A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases. The company leverages its proprietary Kinoid technology to develop treatments, particularly for chronic autoimmune and inflammatory disorders. Its lead candidate, IFNa Kinoid, an anti-interferon alpha vaccine, is currently undergoing Phase IIb clinical trials for systemic lupus erythematosus and Phase IIa trials for dermatomyositis, with further preclinical investigation for diabetes. Neovacs' pipeline also includes VEGF-Kinoid, which is in preclinical development for both age-related macular degeneration and various solid tumors. Additionally, IL-4/IL-13 Kinoid is in preclinical stages for allergy treatments. The company has a significant partnership with the Sunnybrook Research Institute, focusing on the preclinical advancement of VEGF Kinoid specifically for colorectal and ovarian cancers.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is 'cheap' on EV/EBITDA.